P

PharmaResearch Co Ltd
KOSDAQ:214450

Watchlist Manager
PharmaResearch Co Ltd
KOSDAQ:214450
Watchlist
Price: 393 500 KRW 3.55%
Market Cap: 4.1T KRW
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one PharmaResearch Co Ltd stock under the Base Case scenario is 331 058.55 KRW. Compared to the current market price of 393 500 KRW, PharmaResearch Co Ltd is Overvalued by 16%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
331 058.55 KRW
Overvaluation 16%
Relative Value
Price
P
Worst Case
Base Case
Best Case

Valuation Multiples

11.7
P/S
P/S
Price to Sales
11.7
vs History
0
vs Industry
43
Median 3Y
5.1
Median 5Y
5.3
Industry
6.9
Forward
9
More Details
44.4
P/E
P/E
Price to Earnings
44.4
vs History
0
vs Industry
5
Median 3Y
19.1
Median 5Y
19.5
Industry
22.4
Forward
29.9
More Details
29.2
P/OCF
P/OCF
Price to OCF
29.2
vs History
3
vs Industry
7
Median 3Y
16.3
Median 5Y
17.2
Industry
19.1
More Details
37.4
P/FCFE
P/FCFE
Price to FCFE
37.4
vs History
26
vs Industry
5
Median 3Y
24
Median 5Y
29.4
Industry
23.2
More Details
7.6
P/B
P/B
Price to Book Value
7.6
vs History
0
vs Industry
15
Median 3Y
3
Median 5Y
2.7
Industry
2.5
More Details
11
EV/S
EV/S
Enterprise Value to Sales
11
vs History
0
vs Industry
36
Median 3Y
4.5
Median 5Y
4.8
Industry
7.5
Forward
8.5
More Details
15.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
15.3
vs History
0
vs Industry
32
Median 3Y
6.3
Median 5Y
7.1
Industry
8.9
More Details
27.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
27.5
vs History
0
vs Industry
6
Median 3Y
11.6
Median 5Y
12.4
Industry
4
Forward
20.7
More Details
30.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
30.5
vs History
0
vs Industry
5
Median 3Y
13.2
Median 5Y
15.1
Industry
3.7
Forward
22.1
More Details
27.5
EV/OCF
EV/OCF
Enterprise Value to OCF
27.5
vs History
0
vs Industry
7
Median 3Y
14.6
Median 5Y
15.2
Industry
4.5
More Details
38
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
38
vs History
17
vs Industry
4
Median 3Y
19.1
Median 5Y
22.4
Industry
3.4
More Details
9.4
EV/IC
EV/IC
Enterprise Value to IC
9.4
vs History
0
vs Industry
24
Median 3Y
3
Median 5Y
2.7
Industry
4.6
More Details

Multiples Across Competitors

Competitors Multiples
PharmaResearch Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
PharmaResearch Co Ltd
KOSDAQ:214450
4.1T KRW 11.7 44.4 27.5 30.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 067 711 -166 671.6 -202 392.5 -200 083
US
Abbvie Inc
NYSE:ABBV
327.7B USD 5.8 77.3 15.4 23.2
US
Amgen Inc
NASDAQ:AMGN
146.1B USD 4.4 35.7 14.8 26.3
US
Gilead Sciences Inc
NASDAQ:GILD
122.4B USD 4.3 255.1 10.1 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
110.6B USD 10 -206.5 22.4 23.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 008.9 -512.6 -558.2 -543.3
AU
CSL Ltd
ASX:CSL
116.2B AUD 4.9 27.2 16.8 21
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.3B USD 4.2 13.7 8.2 9.1
US
Seagen Inc
F:SGT
39.3B EUR 19.4 -59.3 -63.9 -57.7
NL
argenx SE
XBRU:ARGX
30.5B EUR 15.7 41.4 -2 340 -1 568.9
P/S Multiple
Revenue Growth P/S to Growth
KR
P
PharmaResearch Co Ltd
KOSDAQ:214450
Average P/S: 3 188 163.7
11.7
25%
0.5
FR
Pharnext SCA
OTC:PNEXF
35 067 711
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
7%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.4
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.3
3%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
2 008.9
N/A N/A
AU
CSL Ltd
ASX:CSL
4.9
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
6%
0.7
US
S
Seagen Inc
F:SGT
19.4
30%
0.6
NL
argenx SE
XBRU:ARGX
15.7
39%
0.4
P/E Multiple
Earnings Growth PEG
KR
P
PharmaResearch Co Ltd
KOSDAQ:214450
Average P/E: 70.7
44.4
29%
1.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 671.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.3
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
35.7
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
255.1
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -206.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -512.6 N/A N/A
AU
CSL Ltd
ASX:CSL
27.2
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.3 N/A N/A
NL
argenx SE
XBRU:ARGX
41.4
28%
1.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
P
PharmaResearch Co Ltd
KOSDAQ:214450
Average EV/EBITDA: 16.5
27.5
29%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 392.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
14.8
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
7%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.4
18%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.2 N/A N/A
AU
CSL Ltd
ASX:CSL
16.8
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.2
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 340 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
P
PharmaResearch Co Ltd
KOSDAQ:214450
Average EV/EBIT: 20.9
30.5
34%
0.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 083 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.3
31%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -543.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.1
13%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 568.9 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.